Skip to Main Content
Our COVID-19 ResponseLearn More

Sawai Receives Approval for Vardenafil Tablets

Osaka, Japan – June 3, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Vardenafil tablets (the branded product: LEVITRA®).

Vardenafil tablets are prescribed for the treatment of erectile dysfunction.

The products approved by MHLW on June 3.

Product Name:

VARDENAFIL Tablets 10 mg [SAWAI], 20 mg [SAWAI]

Generic name:

Vardenafil

Brand products:

LEVITRA® 10 mg, 20 mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.